soul trial oral semaglutide cardiovascular outcomes nejm 2024 2025 (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine Oral Semaglutide's Impact on Cardiovascular

Seek support from NHS weight management services or counselling if you struggle with motivation or find yourself reverting to previous eating patterns

Researchers use GHRH fragments in studies examining growth hormone axis signaling and pulsatile endocrine regulation

Paragraph IV filing data, publicly available through the FDA Orange Book, gives PBM formulary teams early intelligence on generic entry timelines that manufacturers should be actively monitoring

Regular physical activity offers numerous benefits for postpartum women

However, certain health situations require extra caution

16 Cardiovascular outcomes The cardiovascular outcomes trial for tirzepatide, SURPASS-CVOT, is an active-comparator study versus dulaglutide 1.5 mg weekly and is ongoing